Ovarian Cancer
An investigation of whether adding a maintenance therapy regimen of olaparib combined with bevacizumab provided a benefit beyond first progression in patients with newly diagnosed advanced high‐grade ovarian carcinoma.
A recent study explores niraparib’s efficacy, safety, and effect on quality of life in compared age-groups.
In patients with high-grade ovarian cancer harboring BRCA mutations and a confirmed response to rucaparib, BRCA homozygous deletion or rearrangement was associated with a significantly longer duration of response.
Despite substantial rates of intraoperative tumor spillages, patients with ovarian germ cell tumors (OGCTs) had an excellent prognosis, and adjuvant chemotherapy showed evidence of preventing disease recurrence.
Is subsequent chemotherapy less effective for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer who have been treated with olaparib as maintenance therapy? Here we discuss the latest findings from the SOLO2/ENGOT Ov-21 clinical trial.
Due to a variety of factors, first-line therapy with atezolizumab failed to demonstrate significant activity in patients with newly diagnosed stage III or stage IV ovarian cancer.
Olaparib maintenance monotherapy not only delays disease progression but also improves overall survival (OS) in women with platinum-sensitive relapsed ovarian cancer and a BRCA mutation.
This real-world study based primarily on community-based practice data showed that a key predictor of time to next treatment and mortality in patients with advanced ovarian cancer was visible residual disease.
With a follow-up of >5 years, women with relapsed platinum-sensitive ovarian cancer and a BRCA mutation who participated in the multicenter phase 3 SOLO2 trial lived >1 year longer if randomized to maintenance olaparib compared with placebo, according to data released at the ASCO20 Virtual Scientific Program.
- Zejula Now Approved for Late-Line Ovarian Cancer
- Trump Set to Nominate Hahn as FDA Commissioner
- FDA Aims to Improve Breast Implant Guidance
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512